Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ABSI

Absci Corporation

Healthcare | Biotechnology
$7.00 -0.27 (-3.71%) as of 2026-07-16 00:47 UTC
Market Cap$960M
Volume3.84M
EPS (TTM)$-0.84

Absci Corporation (NASDAQ: ABSI) is a $960M biotechnology company trading at $7.00 (−3.7% today). Figures from SEC EDGAR and market feeds; updated 2026-07-16 00:47 UTC.

52-Week Range
Low $2.24High $8.17

What Absci Corporation does

Absci is a clinical-stage biopharmaceutical company that uses artificial intelligence to design antibody-based therapeutics through its Integrated Drug Creation platform, which combines generative AI models with laboratory validation. The company has advanced its first two programs to clinical development in approximately two years at an investment of approximately $15 million per program. Its lead candidate, ABS-201, is an anti-prolactin receptor antibody being tested for androgenetic alopecia and endometriosis, both conditions with large patient populations and limited treatment options.

Summarized from Absci Corporation’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price$7.00
Change (1D)-0.27 (-3.71%)
Market cap$960M
Volume3.84M shares
52-week range$2.24 – $8.17
Valuation
EPS (TTM)$-0.84
Price/book5.07×
Returns
52-week return+212.5%

Revenue, margins & earnings

FY2021: net loss $101M on revenue $4M$4MFY2021FY2022: net loss $105M on revenue $5M$5MFY2022FY2023: net loss $111M on revenue $6M$6MFY2023FY2024: net loss $103M on revenue $5M$5MFY2024FY2025: net loss $115M on revenue $3M$3MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-06
  • 2026-07-06Szela Mary TBUY12,900$148.9K
  • 2026-06-26McClain SeanChief Executive OfficerF-59,896$603.5K
  • 2026-06-15Szela Mary TA33,200—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • FMR LLC22,550,997$67.65M+0.8%
  • ARK Investment Management LLC13,726,169$41.18M+9.4%
  • BlackRock, Inc.11,255,194$33.77M-0.7%
View QoQ ownership changes →

Company news

View all →

Questions this page answers

What does Absci Corporation do?

Absci is a clinical-stage biopharmaceutical company that uses artificial intelligence to design antibody-based therapeutics through its Integrated Drug Creation platform, which combines generative AI models with laboratory validation.

What is ABSI's valuation?

ABSI trades at $7.00, as of 2026-07-16.

When did ABSI last file with the SEC?

Absci Corporation's most recent SEC filing on record is a 8-K filed 2026-06-24. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-16 00:47 UTC. This page is also available as JSON at /api/data?ticker=ABSI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ABSI and 3,500+ tickers.

Create a free account — keep ABSI
For your agent
GET /api/data?ticker=ABSI

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt